生技產業產學研研發成果企業加值教育訓練(二)1050628
| 生技產業產學研研發成果企業加值教育訓練(二) 美國專利商標局有關生命科學專利標的適格性新例 (USPTO’s New Subject Matter Eligibility Examples for Life Sciences) 爲積極有效促進國內生技學研單位與新興生技企業創新發展， 生技育成聯盟服務平台整合市場分析、檢驗測試、臨床試驗、 |
¡執行單位：財團法人生物技術開發中心、惇安智慧財產管理股份有
¡舉辦日期：中華民國105年6月28日(二)，下午13:30 - 16:30
¡活動地點：南港生技育成中心大會議室 (台北市南港區園區街3號F棟17樓)
¡報名方式：線上報名，2016/06/27(一)止
¡報名網址：http://www.dcb.org.tw/
¡費用：免費
¡洽詢專線：李佳玲 02-26558633 分機8006
¡議程：
| 時間 | 主題 | 主講人 |
| 13:30-13:50 | 報到 | |
| 13:50-14:00 | 致歡迎詞 | 南港生技育成中心 |
| 14:00-16:00 | 美國專利商標局有關生命科學專利標的適格性新例 –較有利於有關診斷方法及天然物發明專利申請的審查原則? (USPTO’s New Subject Matter Eligibility Examples for Life Sciences –Better guidance for pursuing diagnostic and “natural-product” based inventions?) | 主講人(Speaker)： Dr. Y. Jenny Chen Wolf, Greenfield & Sacks, P.C. |
| 16:00-16:30 | Q&A | 主持人： 王惠玲顧問 惇安智慧財產管理股份有限公司 |
一、課程內容摘述:
題目：美國專利商標局有關生命科學專利標的適格性新例
–較有利於有關診斷方法及天然物發明專利申請的審查原則?
USPTO’s New Subject Matter Eligibility Examples for Life Sciences
- Better guidance for pursuing diagnostic and “natural-product” based inventions?
In view of the U.S. Supreme Court’s decisions in Alice, Myriad, and Mayo, the U.S. Patent and Trademark Office (“USPTO”) has issued a series of guidance on patent subject matter eligibility under 35 U.S.C. § 101, including the Interim Guidance on Subject Matter Eligibility issued in December 2014 and the follow-on Update on Subject Matter Eligibility issued in July 2015. In May 2016, the USPTO further provided new Subject Matter Eligibility Examples for life science inventions.
The May 2016 new examples illustrate the application of the “significantly more” and “markedly different” analysis to various aspects of life science inventions, including vaccine, diagnosis and treatment, dietary sweetener, screening for genetic alterations, paper-making machine, and hydrolysis of fat. The majority hypothetical sample claims provided in these new examples are considered as directed to patent eligible subject matter, providing teaching points for pursuing patent-eligible subject matter in common aspects of life science technologies.
These updated new examples are not binding law and may subject to revisions in compliance with federal courts’ further clarification of the parameters to patent eligibility. Nonetheless, such examples reflect the USPTO’s current positions with respect to the application of the patent eligibility requirement to life science inventions. They are useful guidance to patent prosecutors for drafting claims and responding to rejections under 35 U.S.C. § 101.
二、講者資歷:
Dr. Y. Jenny Chen
Shareholder
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue | Boston, MA 02210-2206
617.646.8000 | 617.646.8646 fax
Email:Yahua.Chen@
Direct: 617.646.8372
Jenny Chen focuses her practice on U.S. and foreign patent prosecution and portfolio strategy, opinion work, due diligence, and post-grant matters such as interference, inter partes review, and reexamination. Jenny counsels clients in the areas of biological, medical, and pharmaceutical sciences. She has worked on projects related to biosimilars, diagnosis and treatment for various diseases, vaccine technologies, drug discovery, antibiotic biosynthesis, medical implants, gene- and cell-based therapies, pharmaceutical formulations, and herb extracts.
Prior to joining the firm, Jenny was an associate at Occhiuti Rohlicek & Tsao, LLP in Cambridge, MA, a law clerk and associate at Fish & Richardson, PC., Boston, MA, an intern at a pharmaceutical company, and an intern at Great Boston Legal Service. Jenny was previously a postdoctoral fellow in the laboratory of Dr. David Hafler at Brigham & Women’s Hospital, Harvard Medical School. Her research focused on T cell activity in autoimmune diseases such as Type I diabetes. Jenny received her Ph.D. degree from Baylor College of Medicine, specializing in molecular biology and pharmacology.
王惠玲顧問
董事長/總經理
惇安智慧財產管理股份有限公司
105台北市松山區敦化北路122號11樓
Email: [email protected]
王惠玲顧問具有二十餘年之智慧財產相關工作經驗，
王顧問現為國立陽明大學兼任助理教授，及經濟部智慧財產局委託「
王顧問曾參與經濟部智慧財產局發明審查基準研究計畫案，
